Molecular Markers in Predicting Lung Cancer Development Using Tissue Samples From Healthy Participants

• Collection of biological specimens from healthy participants with no known risk of lung cancer to use as controls in the study of lung cancer progression [ Designated as safety issue: No ]
• Identification of new molecular abnormalities specific to the development of squamous cell carcinoma of the lung [ Designated as safety issue: No ]
• Selection of important genes/proteins differentially expressed between study groups (e.g., normal vs low-grade vs high-grade vs invasive) and between normal smokers vs normal non-smokers [ Designated as safety issue: No ]

• Identification of new molecular abnormalities specific to the development of squamous cell carcinoma of the lung [ Time Frame: off-study date, up to one year ] [ Designated as safety issue: No ]
• Selection of important genes/proteins differentially expressed between study groups (e.g., normal vs low-grade vs high-grade vs invasive) and between normal smokers vs normal non-smokers [ Time Frame: off-study date, up to one year ] [ Designated as safety issue: No ]

RATIONALE: Studying samples of blood, urine, sputum, mouth cells, and bronchial tissue from healthy participants in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors learn more about the development of cancer.

PURPOSE: This laboratory study is looking for molecular markers in predicting lung cancer development using tissue samples from healthy participants.

OBJECTIVES:

• To obtain biological specimens from healthy participants with no known risk of lung cancer to use as controls in the study of lung cancer progression.
• To identify new molecular abnormalities specific to the development of squamous cell carcinoma of the lung.

OUTLINE: Serum, urine, sputum, and buccal cell samples are collected. Patients also undergo bronchoscopy for collection of bronchial tissue and bronchial brush samples. The samples are used for genomic and proteomic studies to identify new molecular abnormalities specific to the development of lung cancer.

Healthy, non-smokers.

• Healthy, no Evidence of Disease
• Lung Cancer

• Genetic: proteomic profiling
  Collection of tissue, blood, urine, mouth cells, spit, nasal airway cells and breath
• Other: biologic sample preservation procedure
  Collection of tissue, blood, urine, mouth cells, spit, nasal airway cells and breath
• Other: laboratory biomarker analysis
  Collection of tissue, blood, urine, mouth cells, spit, nasal airway cells and breath
• Procedure: bronchoscopy
  Collection of breath condensate.

DISEASE CHARACTERISTICS:

• Healthy participant

  • No history of smoking
  • No history of cancer

PATIENT CHARACTERISTICS:

• SWOG performance status 0
• No clinically apparent bleeding diathesis

PRIOR CONCURRENT THERAPY:

• Not specified